54
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          CT-011 is a humanized IgG1 monoclonal antibody that modulates the immune response through interaction with PD-1, a protein belonging to the B7 receptor family present on lymphocytes. The objectives of this phase I study were to assess the dose-limiting toxicities, to determine the maximum tolerated dose, and to study the pharmacokinetics of CT-011 administered once to patients with advanced hematologic malignancies.

          Related collections

          Author and article information

          Journal
          Clin Cancer Res
          Clinical cancer research : an official journal of the American Association for Cancer Research
          American Association for Cancer Research (AACR)
          1078-0432
          1078-0432
          May 15 2008
          : 14
          : 10
          Affiliations
          [1 ] Institute of Oncology and Radiotherapy, Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel.
          Article
          14/10/3044
          10.1158/1078-0432.CCR-07-4079
          18483370
          c5ed7b58-e094-4fd7-b135-37ed2684ec51
          History

          Comments

          Comment on this article